General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Background
Hemolytic uremic syndrome is defined as non-immune microangiopathic hemolytic anemia, thrombocytopenia and renal failure. A subtype, termed atypical HUS (aHUS), is associated with activation of the alternative pathway of complement (1) . Mutations have been identified in complement regulators factor H, factor I, membrane-cofactor protein (MCP), and complement factors C3 (2) and factor B. Deletions were found in factor H-related proteins 1 and 3, often associated with anti-factor H antibodies. In addition, mutations have been found in thrombomodulin (mutations reviewed in (1)).
Membranoproliferative glomerulonephritis (MPGN) is a distinct renal disease presenting with hematuria, proteinuria, hypertension and impaired renal function. MPGN is sub-classified based on the localization of immune deposits consisting of IgG and/or C3 (3). MPGN types I and III are considered to be immune complex-mediated diseases whereas type II, also known as dense deposit disease, is associated with complement activation via the alternative pathway (3).
Both aHUS and MPGN can thus be associated with activation of the alternative pathway of complement. Certain cases have been described in which individuals present with a combined clinical picture of aHUS and MPGN type I (4), indicating that these conditions may have a common molecular background.
A four-year old boy was investigated at the Department of Pediatrics, Section of Pediatric Nephrology of the Haukeland University Hospital in Bergen. He is referred to as Patient III1.
He was asymptomatic at the time of primary investigation and had not previously exhibited any signs or symptoms of renal disease but underwent a medical examination because his younger sister had an episode of aHUS. The initial examination revealed a clinically healthy child with normal blood pressure. Urinalysis revealed proteinuria, microscopic hematuria and casts. Blood and urine tests are summarized in supplementary Table 1 .
Complement levels taken when the patient was first examined showed normal levels (supplementary Table 2 ). Ultrasound of the kidneys showed mildly increased parenchymal echogenicity. A renal biopsy was performed. The results are presented in supplementary Table 3 and Figure 1a -c. The biopsy showed glomerular basement membrane (GBM) thickening with double contours, mesangial cell proliferation, endothelial cell swelling and deposits of C3, IgG and IgM. Electron microscopy revealed subendothelial and mesangial electron dense deposits as well as mesangial cell interposition and podocyte foot effacement.
The patient was treated with an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker and remained asymptomatic.
At the age of 6 his creatinine levels started to rise and he exhibited increased proteinuria. He underwent a second renal biopsy (supplementary Table 3 , Figure 1d ). As in the first biopsy thickening of the GBM, with double contours, and narrowing or occlusion of glomerular capillaries were noted. In addition, mild tubular atrophy and interstitial fibrosis were demonstrated. Blood samples were repeatedly assessed during symptom-free periods and during infections but no laboratory parameters indicated HUS.
At the age of 6.5 years the patient developed hypertension and by the age of 8 years he was treated with four anti-hypertensive medications. He was stable on this treatment until just before he turned 10 when his creatinine and proteinuria increased and glomerular filtration rate decreased (supplementary Table 1 ). He underwent a third renal biopsy at 10 years ( Figure   1e -g). The biopsy showed global sclerosis of 12/17 glomeruli and the remaining glomeruli exhibited mesangial expansion due to increased matrix and cells. Endothelial cells were swollen and glomerular capillaries were thickened or occluded. One thrombus was noted in a capillary ( Figure 1e ). Glomerular basement membranes were thickened with double contours.
Arterioles and smaller arteries showed media hypertrophy. Immunohistochemistry showed, as in previous biopsies, labeling with C3 and C1q (Figure 1f ). Electron microscopy showed electron dense precipitations in capillary lumina, mesangial cell interposition and podocyte foot process effacement ( Figure 1g ).
Currently, at the age of 10 years, the patient's clinical condition has deteriorated with decreased renal function and increased blood pressure refractory to treatment with a combination of five anti-hypertensive medications. The laboratory values for the first time Patients II1, II2, II4, III1, III2 and III7 carry a previously described MCP mutation (Y155D) (5) and two C3 mutations: R713W (in exon 17) and G1094R (in exon 26). R713W has been previously described (2) , whereas G1094R is a novel mutation situated one amino acid from a described mutation at position D1093N (2). These C3 mutations were presumably localized on the same allele due to the common pattern of inheritance and they were not found in DNA from 100 healthy controls. In addition, Patient III1 has a heterozygous deletion of CFHR1/3 and auto-antibodies to CFH were detected upon debut of disease but not five years later. The MCP mutation was found in two unaffected family members and the C3 mutations were found in one unaffected family member. The mutations and their presumed functional consequences are presented in Figure 2 and supplementary Table 4 , as well as the supplementary results and discussion.
Discussion
In this report we describe a child with progressive renal failure and pathology exhibiting a membranoproliferative pattern. Other family members presented with features of aHUS. All affected family members were found to share complement mutations in C3 and MCP. This Furthermore, strong C1q labeling is not found in thrombotic microangiopathy but usually associated with systematic lupus erythematosis, C1q nephropathy (6) or MPGN type I but the weak IgG staining suggests that the renal deposits were probably not mediated by immune complexes. The finding of membranoproliferative features is in line with other studies suggesting that there might be a continuous spectrum of morphological changes from thrombotic microangiopathy to MPGN (7) (8) (9) . This group of disorders could also encompass the more recently described C3 glomerulopathy with isolated C3 deposits (10) . However, the strong C1q labeling in the patient's biopsies is not compatible with this diagnosis.
The presence of complement activation due to mutations in C3 and MCP enabled the pathological features to progress even in the absence of overt HUS. The clinical and pathological features overlap with MPGN type I indicating that aHUS and MPGN may share a common molecular background. We thus conclude that this patient exhibited an unusual presentation of chronic thrombotic microangiopathy mimicking MPGN type I.
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Figure legends
No documented abnormality. Normal C3 binding to CFB, CFH, MCP and soluble CR1.
Associated with the presence of anti-CFH antibodies. (primers available upon request) were bidirectionally sequenced using the Big dye terminator kit (Applied Biosystems, Foster City, CA) and analyzed on an Applied Biosystems DNA Analyzer, model 3730. Multiplex ligation-dependent probe amplification was used to quantify the number of allele copies of the CFHR1 and CFHR3 genes as previously described (5) . The C3 and MCP gene mutations were sequenced in all family members except individuals III 4 and III 5. DNA from patient III 1 was further sequenced for the CFH and CFI genes as well as copy numbers of the CFHR1 and CFHR3 genes. Analysis of serum antibodies to CFH was performed by ELISA as previously described.(6) CFB: factor B, CFH: factor H, CFI: factor I, MCP: membrane cofactor protein/CD46. a , Depicted as mean fluorescence intensity (MFI) analyzed by flow cytometry. b , Patients II 2 and II 4 presented with low levels of serum C3 during episodes of aHUS. C3 levels remained low for years even during remission. c , C3 levels were repeatedly normal, C3 nephritic factor was negative. This patient exhibited normal serum C3 levels until the age of 10 years when levels just under normal reference values were detected.
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